Armed with the positive results of an external validation study that were unveiled during a conference in San Francisco earlier this year, Everist Genomics (Ann Arbor, Michigan) has reported the worldwide commercial availability of its OncoDefender-CRC colorectal cancer assay. (Medical Device Daily)